Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00003518 · ClinicalTrials.gov registry record · Phase 2

Paclitaxel Plus Gemcitabine in Treating Patients With Refractory Metastatic Germ Cell Tumors

A Phase 2 study of Ovarian Cancer and Testicular Germ Cell Tumor, sponsored by Eastern Cooperative Oncology Group.

Completed
Registry status
Phase 2
Development phase
44
Enrollment target
19
Study locations

NCT00003518 is a Phase 2 study of Ovarian Cancer and Testicular Germ Cell Tumor that has completed, run by Eastern Cooperative Oncology Group. The registered enrollment target is 44 participants, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (94% lower). The trial reports 19 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00003518, a Phase 2 study of Ovarian Cancer and Testicular Germ Cell Tumor, has completed, sponsored by Eastern Cooperative Oncology Group.

COMPLETED
Registry status
Phase 2
Development phase
44 participants
Enrollment target
19
Study locations

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of paclitaxel plus gemcitabine in treating patients with refractory metastatic germ cell tumors that have not responded to surgery or chemotherapy.

Conditions Studied

Ovarian Cancer Testicular Germ Cell Tumor

Interventions

  • DRUG paclitaxel
  • DRUG gemcitabine hydrochloride

Study Locations (19)

Illinois

  • Robert H. Lurie Comprehensive Cancer Center, Northwestern University - Chicago
  • Veterans Affairs Medical Center - Chicago (Lakeside) - Chicago
  • CCOP - Carle Cancer Center - Urbana

New Jersey

  • Hackensack University Medical Center - Hackensack
  • Kimball Medical Center - Lakewood
  • Morristown Memorial Hospital - Morristown

Indiana

  • Indiana University Cancer Center - Indianapolis
  • Veterans Affairs Medical Center - Indianapolis (Roudebush) - Indianapolis

Colorado

  • CCOP - Colorado Cancer Research Program, Inc. - Denver

Iowa

  • CCOP - Cedar Rapids Oncology Project - Cedar Rapids

Louisiana

  • CCOP - Ochsner - New Orleans

Massachusetts

  • Beth Israel Deaconess Medical Center - Boston

Michigan

  • CCOP - Kalamazoo - Kalamazoo

Trial Details

FieldValue
Enrollment Target 44 participants
Start Date 1999-01-25
Phase Phase 2

Sponsor

Eastern Cooperative Oncology Group

141 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00003518

The ClinicalTrials.gov registry entry for NCT00003518 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (94% lower). The listed sponsor is Eastern Cooperative Oncology Group, which has 141 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 2 interventions - of which paclitaxel is the first listed.

NCT00003518 reports 19 study locations spanning 14 distinct geographic areas - top geographies include Illinois, New Jersey, Indiana.

Frequently Asked Questions

What is clinical trial NCT00003518 about?

NCT00003518 is a clinical study titled "Paclitaxel Plus Gemcitabine in Treating Patients With Refractory Metastatic Germ Cell Tumors". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of paclitaxel plus gemcitabine in treating patients with refractory meta...

What is the current status of trial NCT00003518?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 1999-01-25.

What conditions does trial NCT00003518 study?

This clinical trial studies the following conditions: Ovarian Cancer, Testicular Germ Cell Tumor.

What interventions are being tested in trial NCT00003518?

The interventions under investigation include: paclitaxel (DRUG), gemcitabine hydrochloride (DRUG).

Who is sponsoring clinical trial NCT00003518?

This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00003518 being conducted?

This trial has 19 study locations across Colorado, Illinois, Indiana, Iowa, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Ovarian Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Ovarian Cancer

All registered trials for this condition

Testicular Germ Cell Tumor

All registered trials for this condition

Colorado

All trials with a study site in Colorado

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.